Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2] - The business model of Tempus-acquired Ambry is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2] - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Financial Impact - Following the release of a report by Spruce Point Capital Management that highlighted various red flags regarding Tempus' management and operations, the stock price fell by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [3][4]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action against Tempus AI, with options to serve as lead plaintiff or remain an absent class member [5].
TEM Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Tempus AI, Inc. Class Action